Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1826-1832

  Xylinas, E ^a,b   Cha, E K ^a   Sun, M ^c   Rink, M ^a,d   Trinh, Q D ^c   Novara, G ^e   Green, D A ^a   Pycha, A ^f   Fradet, Y ^g   Daneshmand, S ^h   Svatek, R S ⁱ   Fritsche, H M ^j   Kassouf, W ^k   Scherr, D S ^a   Faison, T ^a   Crivelli, J J ^a   Tagawa, S T ^a   Zerbib, M ^b   Karakiewicz, P I ^c   Shariat, S F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Paris Descartes University ^*  (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF PADOVA   (Italy)

^f CENTRAL HOSPITAL OF BOLZANO   (Italy)

^g UNIVERSITÉ LAVAL   (Canada)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ Mays Cancer Center at UT Health San Antonio   (United States)

^j UNIVERSITY OF REGENSBURG   (Germany)

^k MCGILL UNIVERSITY   (Canada)

more..

Author keywords

bladder cancer; chemotherapy; nomogram; prediction; radical cystectomy; T1 3 N0

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER UROTHELIAL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CYSTECTOMY; EXTERNAL VALIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PATIENT COUNSELING; PRIORITY JOURNAL; PROBABILITY; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; COUNSELING; CYSTECTOMY; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84870050398     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.464     Document Type: Article

References (31)

1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48(2): 189-199
2. Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24(24): 3967-3972
3. Burger M, Mulders P, Witjes W (2012) Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major european centres: results of a feasibility questionnaire. Eur Urol 61(5): 1070-1071
4. Cheng SC, Fine JP, Wei LJ (1998) Prediction of cumulative incidence function under the proportional hazards model. Biometrics 54(1): 219-228
5. Gakis G, Schwentner C, Todenhofer T, Stenzl A (2012) Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Int 110(2): 233-237
6. Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the Tnr-C score. BJU Int 108(11): 1800-1805
7. Harrell Jr. FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247(18): 2543-2546
8. Harrell Jr. FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4): 361-387
9. Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5): 1039-1047
10. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A (2006a) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176(4 Part 1): 1354-1356
11. Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE (2006b) Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 50(6): 1254-1260
12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10): 766-771
13. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183(6): 2165-2170
14. Nuhn P, May M, Sun M, Fritsche HM, Brookman-May S, Buchner A, Bolenz C (2012) External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol 61(1): 58-64
15. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, Shariat SF (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4): 854-855
16. Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H (2012) Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 187(2): 457-462
17. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y (2008a) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112(2): 315-325
18. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A (2006a) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12(22): 6663-6676
19. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A (2006b) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol 176(6 Part 1): 2414-2422
20. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008b) An updated catalog of prostate cancer predictive tools. Cancer 113(11): 3075-3099
21. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW (2008c) Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 14(14): 4400-4407
22. Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT (2009) Critical review of prostate cancer predictive tools. Future Oncol 5(10): 1555-1584
23. Shariat SF, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI (2008d) Nomograms for bladder cancer. Eur Urol 54(1): 41-53
24. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10): 1402-1412
25. Skuladottir H, Olsen JH (2003) Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol 21(16): 3035-3040
26. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3): 666-675
27. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the Eau guidelines. Eur Urol 59(6): 1009-1018
28. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr. FJ, Dotan ZA, Fearn PA, Kattan MW (2006) Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98(10): 715-717
29. Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH (2009) Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer 115(23): 5460-5469
30. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21): 4602-4608
31. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H (2010) Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 106(3): 342-348